e-learning
resources
Milan 2017
Tuesday, 12.09.2017
Outcomes and new treatment strategies in pulmonary hypertension
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Effect of targeted therapies on survival of schistosomiasis associated pulmonary arterial hypertension
B. Mamprim Piloto (SAO PAULO/SP, Brazil)
Source:
International Congress 2017 – Outcomes and new treatment strategies in pulmonary hypertension
Session:
Outcomes and new treatment strategies in pulmonary hypertension
Session type:
Poster Discussion
Number:
3524
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
B. Mamprim Piloto (SAO PAULO/SP, Brazil). Effect of targeted therapies on survival of schistosomiasis associated pulmonary arterial hypertension. 3524
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Impact of initial treatment strategy on long-term survival in pulmonary arterial hypertension (PAH)
Source: International Congress 2018 – Risk stratification in treatment of pulmonary arterial hypertension
Year: 2018
Is survival in patients with severe group 3 pulmonary hypertension influenced by targeted therapy?
Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights
Year: 2015
Impact on survival of pulmonary function abnormalities in pulmonary arterial hypertension
Source: Annual Congress 2009 - Pulmonary hypertension
Year: 2009
Combined treatment in pulmonary hypertension
Source: International Congress 2016 – GR3 Scientific Grand Round: precision medicine
Year: 2016
Improving survival in pulmonary arterial hypertension
Source: Eur Respir J 2005; 25: 218-220
Year: 2005
Audit of disease targeted therapies in adult patients with pulmonary arterial hypertension
Source: International Congress 2017 – Outcomes and new treatment strategies in pulmonary hypertension
Year: 2017
Effect of long-term specific therapy in a cohort of 33 patients with pulmonary arterial hypertension of various etiologies
Source: Annual Congress 2010 - Pulmonary circulation II
Year: 2010
The future of treatment for pulmonary arterial hypertension
Source: ERS Skills course - Pulmonary hypertension and pulmonary vascular disease
Year: 2018
The future of treatment for pulmonary arterial hypertension
Source: ERS Course 2017 - Pulmonary Hypertension and Pulmonary Vascular Disease
Year: 2017
The future of treatment for pulmonary arterial hypertension
Source: School Course 2014 - Pulmonary Hypertension and Pulmonary Vascular Disease
Year: 2014
The future of treatment for pulmonary arterial hypertension
Source: School Course 2012 - Pulmonary hypertension and pulmonary vascular disease
Year: 2012
The role of combination therapy in managing pulmonary arterial hypertension
Source: Eur Respir Rev 2014; 23: 469-475
Year: 2014
Adherence to disease-specific drug treatment among patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension
Source: ERJ Open Res, 6 (4) 00299-2020; 10.1183/23120541.00299-2020
Year: 2020
Effect of pulmonary arterial hypertension on outcome of pulmonary tuberculosis
Source: Annual Congress 2011 - Clinical tuberculosis
Year: 2011
Long-term riociguat treatment towards implementing a targeted treatment strategy in patients with idiopathic pulmonary arterial hypertension
Source: Virtual Congress 2020 – Epidemiology and treatment of pulmonary arterial hypertension
Year: 2020
Impact of therapies on insulin resistance in pulmonary arterial hypertension
Source: Annual Congress 2010 - Pulmonary circulation: clinical aspects
Year: 2010
Adherence to pulmonary arterial hypertension targeted therapies
Source: International Congress 2015 – Pulmonary hypertension: management
Year: 2015
Optimal management of severe pulmonary arterial hypertension
Source: Eur Respir Rev 2011; 20: 254-261
Year: 2011
Update on current treatment options of pulmonary hypertension
Source: Annual Congress 2006 - Pulmonary hypertension at the crossroads of science and clinical medicine
Year: 2006
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept